A5029934735- Pharmaceutical industry and healthcare
- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
- Healthcare cost, quality, practices
- Healthcare Quality and Management
- Primary Care and Health Outcomes
- Healthcare Policy and Management
- Pharmaceutical Practices and Patient Outcomes
- Health Services Management and Policy
- Regulation and Compliance Studies
- Medical Malpractice and Liability Issues
- Patient Safety and Medication Errors
- Healthcare Systems and Challenges
- Innovation Policy and R&D
- Health Policy Implementation Science
- Academic Publishing and Open Access
- Social Policy and Reform Studies
- Nursing Roles and Practices
- scientometrics and bibliometrics research
- Risk Perception and Management
- Education in Diverse Contexts
- Clinical practice guidelines implementation
- Diverse Academic Research Studies
- Health and Medical Research Impacts
- Race, Genetics, and Society
University of Bath
2016-2025
Downtown Women's Health Care
2014
University of Leicester
2012
University of Cambridge
2011
Self-regulation of payment disclosure by pharmaceutical industry trade groups is a major global approach to increasing transparency financial relationships between drug companies and healthcare professionals organisations. Nevertheless, little known about the relative strengths weaknesses self-regulation across countries, especially beyond Europe. To address this gap in research stimulate international policy learning, we compare UK Japan, likely strongest cases Europe Asia, three dimensions...
From 2012 to 2016 the drug industry donated over £57m (€65m; $73m) UK patient organisations, with annual sum more than doubling periodThe funding benefited a small number of organisations and activities related research public involvementThe gave priority commercially high profile conditions
Quality improvement collaboratives (QICs) continue to be widely used, yet evidence for their effectiveness is equivocal. We sought explain what happened in Stroke 90:10, a QIC designed improve stroke care 24 hospitals the North West of England. Our study drew part on literature collective action and inter-organizational collaboration. This has been relatively neglected evaluations QICs, even though they are founded principles co-operation sharing. interviewed 32 professionals that...
Drug company payments to health care organizations can create conflicts of interest. However, little is known about such financial relationships, especially outside the United States.To examine concentration and patterns drug in Kingdom.This cross-sectional study examined nonresearch reported industry-run Disclosure UK database. Companies participating 2015 receiving their were included analysis. The data analyzed descriptively at organization, payment, donor levels, considering organization...
Objectives To analyse the section of Disclosure UK that pertains to healthcare professionals (HCPs) in order provide insight into database’s structure and content suggest ways improve its transparency. Design participants Cohort study drug companies HCPs 2015 2016 versions UK. Results Companies report transfers value (ToVs) named or, where an HCP declines consent, aggregate. Only a limited number variables describe recipient ToV, precluding refined analyses. In 2015, 107 reported 54 910 ToVs...
Abstract The European pharmaceutical industry uses the alleged efficacy of self-regulation to question need for transparency laws similar US Physician Payment Sunshine Act. We conducted a comparative analysis 20 large companies’ payment disclosures in seven countries 2017–2019. data was extracted as part eurosfordocs.eu, novel project that scrapes and integrates publicly available databases disclosures. Our EUR 735 million showed marked differences country patterns. For example, totals per...
Objective To assess financial conflicts of interest (COI) and nonfinancial COI among psoriatic arthritis (PsA) clinical practice guideline (CPG) authors in Japan the US, to evaluate quality evidence strength recommendations PsA CPGs. Methods We performed a retrospective analysis using payment data from major Japanese pharmaceutical companies US Open Payments Database 2016 2018. All CPGs issued by Dermatological Association (JDA) American College Rheumatology (ACR) were included. Results Of...
Medical device industry payments to healthcare organisations (HCOs) can create conflicts of interest which undermine patient care. One way addressing this concern is by enhancing transparency financial support HCOs. MedTech Europe, a medical trade body, operate system disclosure education European This study aimed characterise reported in database and evaluate the system. An observational education-related HCOs Europe was conducted. Data manually extracted from transparentmedtech.eu. The...
Shai Mulinari and Piotr Ozieranski argue healthcare professionals organisations should respond more forcefully to unethical marketing support stronger regulatory action The practices used by pharmaceutical companies have been a longstanding concern,12 with controversial techniques including the use of medical opinion leaders third parties such as patient advocacy groups. In many jurisdictions, Europe,3 Japan,4 Canada,5 Australia,6 is largely regulated industry itself, based on codes practice...
How corporations surveil and influence consumers using big data tools is a major area of research public debate. However, few studies explore it in relation to physicians the USA, even though they have been surveilled targeted by pharmaceutical industry since at least 1950s. Indeed, 2010, concerns about industry's undue led passing Physician Sunshine Act, unique piece transparency legislation that requires companies report their financial ties teaching hospitals database. This article argues...
Abstract Interfirm self‐regulation through trade associations is common but its effectiveness debated and likely varies by time, country, industry. This study examines of pharmaceutical marketing, characterized delegation major regulatory responsibilities to associations' self‐regulatory bodies. In addressing critical research gaps, this first analyzes 1,776 complaints against companies in the UK over 18 years (2004–2021). Findings regarding severe, repeat, complex offending, delays...
A joint investigation by The BMJ and Cambridge Bath universities uncovers how NHS England tried to limit access expensive new drugs for hepatitis C. <b>Jonathan Gornall</b>, <b>Amanda Hoey</b>, <b>Piotr Ozieranski</b> report
Background Many patient organisations collaborate with drug companies, resulting in concerns about commercial agendas influencing advocacy. We contribute to an international body of knowledge on organisation-industry relations by considering payments reported the industry's centralised 'collaboration database' Sweden. also investigate possible motives behind funding assessing its association commercialisation. Methods Our primary data source were 1,337 payment reports from 2014–2018. After...
Background: Financial relationships between healthcare institutions and pharmaceutical companies can lead to conflicts of interest (COIs), potentially compromising patients’ care. In Japan, scholarship donations, unique type payments made their subunits by industries without restricting use including non-educational or research purpose, may often have implicit promotional purposes. However, detailed information about these remains scarce. Methods: This study employed a cross-sectional design...
To explore pharmacy users' perceptions of current and future provision community services in England.
complaints over drug companies' marketing practices in the UK.Hristio Boytchev, Shai Mulinari, and Piotr Ozieranski report
Unknown unknowns'-payments that remain undetected because their existence is not deducible from companies' records.Cumulatively, these layers of uncertainty mean the public only sees 'tip iceberg' payments, with an unknown share being obscured, hidden or completely untraceable (figure 1).The lack full and reliable information about industry financial ties undermines-if on January 7,
Abstract This paper aims to fill in the gap research on effect of pharmaceutical lobbying drug reimbursement policy, particularly Poland, a post-communist country. To this end, we conducted in-depth, semi-structured, anonymous, elite interviews supplemented by review legislation, policy documents, official reports and press articles, as well observations. Overall, 109 representatives stakeholders involved were interviewed. We identified two key methods: informal persuasion third-party...